DOCSLIB.ORG

Update in Pediatric Oncology Pediatric Leukemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Update in Pediatric Oncology Pediatric Leukemia 9/21/2016 Objectives • Review newest therapies in pediatric oncology • Discuss the use of Blinatumomab in pediatric Update in Pediatric Oncology patients • Review Car T‐Cell immunotherapy in pediatric Katie Bruce, PharmD, BCPPS patients Pharmacy Clinical Specialist • Discuss the latest therapy approved for use in Pediatric Oncology and BMT The Children’s Hospital at TriStar neuroblastoma Centennial Disclosure • I have no financial conflicts to disclose Pediatric Leukemia Pediatric Leukemia Classification • Acute lymphoblastic leukemia (ALL) is the most • Over 85% of childhood ALL is B‐cell ALL common cancer in children ▫ Most commonly precursor‐B cell ALL ▫ Accounts for ~30% of all cancers 2% mature B‐cell ALL ▫ 3000 new cases in US each year ▫ 15% T‐cell ALL (Birth –21 years old) Investigating use of nelarabine and/or high dose methotrexate ~ 80% are ALL and ~20% are AML ▫ Incidence of 3.4 cases per 100,000 • Risk Criteria ▫ Most common between 2 and 5 years old ▫ Initial WBC count ▫ Boys > girls ▫ Age • Higher incidence in Caucasians and Hispanics vs. African ▫ Cytogenetics American Children ▫ Immunologic subtype www.curesearch.org www.curesearch.org 1 9/21/2016 Risk Stratification Outcomes • ~85% overall 5‐year event‐free survival ▫ 90 –95 % in low‐ or standard‐risk pre‐B ALL with good response to induction chemotherapy ▫ 75 –85 % in high‐risk with good early response ▫ <75% in very high‐risk (Ph+, hypodiploid, CNS3) or slow response to chemo • T‐cell ALL survival lower at 70 –75 % • Infant ALL ▫ Poor prognosis with 10‐30% event‐free survival www.cancer.gov www.childrensoncologygroup.com Relapsed/Recurrent ALL Relapsed/Recurrent B‐ALL • 20 ‐ 25% relapse or fail initial treatment • Backbone Chemotherapy for relapse B‐ALL ▫ Bone marrow, CNS, testes, lymph nodes Block 1Block 2Block 3 ▫ Aggressive re‐induction, consolidation, ± SCT PRED 40 mg/m2/day, ETOP Days 1‐5 HD ARAC Days 1, 2, 8, ▫ 5 ‐ 60% survival Days 1‐29 CPM Days 1‐5 9 VCR 1.5 mg/m2, Days HDMTX Day 22 with L‐ASP Days 2, 9 1, 7, 15, 21 leucovorin IT MTX or ITT Days 1, • 60‐75% of recurrences occur within first year after PEG 2500 IU/m2 , 22 Days 2, 9, 16, 23 completion of therapy DOXO 60 mg/m2 , on • Rates decrease years 2 ‐ 4 and are rare after 5 years Day 1 post‐treatment IT ARAC Day 1 IT MTX Days 15, 29 (or ITT if CNS positive) www.cancer.gov www.childrensoncologygroup.org Blinatumomab (Blincyto®) Blinatumomab (Blincyto®) • AALL1121‐ Phase I/II trial • Novel agent for B‐linegage malignancies ▫ Early data shows efficacy in relapse patients • Fusion protein ▫ Bispecific T‐cell engager (BiTE®) antibody, dual • AALL1331‐ Phase III trial, currently enrolling patients specificity for CD19 and CD3 ▫ Risk stratification after Block 1 • Through CD3 binding, it recruits and engages T‐cells for lysis of CD19 positive B‐cells ▫ Randomized to Block 2 or blinatumomab • Accelerated approval from FDA for Also may receive salvage blinatumomab if relapsed/refractory B‐cell ALL relapse/refractory on standard therapy ▫ Phase II trial showed CR in 43% of patients after 2 ▫ Dose of blinatumomab 15 µg/m²/24 hours x 4 weeks cycles (Topp et al. Lancet Oncol. 2015a) then one week off www.childrensoncologygroup.org Benjamin JE, Stein AS. Ther Adv Hematol.2016 2 9/21/2016 Blinatumomab (Blincyto®) Blinatumomab (Blincyto®) • Adverse reactions • Continuous infusion over 4 weeks ▫ Cytokine release syndrome (CRS) ▫ Half life‐ 2 hours Chills, fever, flushing, bronchospasm, hypotension Give dexamethasone prior to starting infusion ▫ Reduces adverse reactions because concentrations at ▫ Neurologic steady state Headache, tremor, dizziness, confusion, memory impairment, • Observe in hospital for the first 9 days aphasia, seizures • Stop infusion and give steroids. Should be reversible Bag change every 48 hours ▫ Coagulopathy Prolong activated PTT, fibrinogen decreased, INR increased ▫ Hepatic abnormalities ALT and AST increased, bilirubin increase, GGT increase Benjamin JE, Stein AS. TherAdv Hematol.2016 Benjamin JE, Stein AS. TherAdv Hematol.2016 Chimeric antigen receptor (CAR) T‐cell CAR T‐Cell Therapy: The Process therapy • T‐cells collected from patient • T‐cells re‐engineered in labratory • Adoptive cell therapy (ACT) to produce chimeric antigen • Pediatrics trials in B‐Cell ALL pediatric patients at NCI receptor (CARs) on their surface (CTL019) and CHOP • Expand the CAR T‐cells in the lab • Using CTL019, an antigen that targets CD19 until there are millions ▫ • Patient given chemotherapy CD19 is a B‐cell surface protein preparatory regimen ▫ Universal expression in B‐cell ALL (cyclophosphamide‐based) before infusion • CAR T‐cells infused into patient • Hopefully, CAR T‐cells guard against recurrence https://www.lls.org/treatment/types‐of‐treatment/immunotherapy/chimeric‐antigen‐receptor‐car‐t‐cell‐therapy Maude SL, et al. Blood. 2015 CAR T‐cell Adverse Reactions CAR T‐Cell Therapy • Preliminary results • CRS‐ most common and potentially severe ▫ Potenially correlation to presence of CRS and response to ▫ 90 % CR in 30 adult and pediatric patients (CHOP CAR T‐cells Phase I)¹ ▫ Severity might correlate to tumor burden Probability of persistence of CAR T‐cells at 6 months • Inflammatory response related to exponential T‐cell being 68% proliferation and increased cytokines ▫ ▫ 88% CR in 16 adult patients with relapsed B‐cell ALL at Marked increases in IL‐2, IL‐6, IL‐10 and interferon ▫ Wide range of severity, from flu‐like symptoms to multi‐ Memorial Sloan‐Kettering² organ failure Persistent of CAR T‐cells of 1‐3 months • Tocilizumab‐ IL‐6 inhibitor ▫ 70 % CR in 20 children and adults at NCI³ ▫ Used to treat CRS ▫ Other IL‐6 inhibitors might be effective Average persistence is 68 days • Steroids‐ controversial‐ maybe useful for 2‐4 day burst 1.Maude SL, Frey N, Shaw PA, et al. N Engl J Med. 2014. 2.Davila ML, Riviere I, Wang X, et al. Sci Transl Med. 2014 3.Lee DW, Kochenderfer JN, Stetler‐Stevenson M, et al. Lancet. 2015. Maude SL, et al. Blood. 2015 3 9/21/2016 Incidence and Epidemiology • Solid tumor that originates from primordial neural crest cells that normally give rise to adrenal medulla and sympathetic ganglia Neuroblastoma • Most common extracranial solid tumor in children, accounting for 8 –10 % of childhood malignancies ▫ Accounts for 15% of childhood mortality • 800 cases annually in the US ▫ Median age of diagnosis is 19 months and ~90% diagnosed by age 5 ▫ Occurs more often in males than females (1.2:1) www.cancer.gov Pathogenesis Pathophysiology • Exact cause is unknown • Originates in adrenal medulla or paraspinal site in ▫ Most common cytogenetic abnormalities are deletions sympathetic nervous system or rearrangements of the short arm of chromosome 1 Can present along a spectrum of differentiation from benign ganglioneuroma to ganglioneuroblastoma, or or chromosome 17 malignant neuroblastoma • N‐MYC is an oncogene on chromosome 2 • “Small blue round cell” neoplasm ~25% of patients with neuroblastoma have N‐MYC Differentiate from Ewings, NHL, PNET, amplification rhabdomyosarcoma Associated with advanced stage disease and poor prognosis • 65% are abdominal and 20% are thoracic Maris, J. N Eng J Med. 2010 Maris, J. N Eng J Med. 2010 Signs and symptoms Diagnosis and Staging • Thoracic/pelvic tumor • Orbital tumor • Urine catecholamines (VMA and HVA) are elevated in 85 – 90% of ▫ Abdominal fullness/discomfort ▫ Opsoclonus –myoclonus patients ▫ Bowel or bladder symptoms (Dancing eye syndrome) ▫ Normal VMA < 8 μg/mL and HVA < 17 μg/mL ▫ Hypertension (renal ▫ Proptosis or periorbital ▫ VMA:HVA ratio also important vasculature) ecchymoses Higher the ratio, the better the prognosis ▫ Cord compression (emergency) • Bone lesions • Lab Studies: CBC, liver and kidney function, coags, ferritin, LDH, ▫ Respiratory compromise ▫ Focal pain, limp, refusal to walk neuron specific enolase, and urine catecholamines • Skin nodules (Infants) ▫ Horner’s Syndrome • Diagnostic Imaging: CT of chest, abdomen, pelvis; MRI of head and ▫ Secretory diarrhea secondary to • Nonspecific spine (if indicated), MIBG scan (bone/soft tissue scan), ECHO, GFR increased vasoactive intestinal ▫ Fever, weight loss, generalized peptide pain • Tissue studies: Bilateral bone marrow biopsies and aspirates and tissue from mass large enough for histopathology, N‐MYC Maris, J. N Eng J Med. 2010 amplification, cytogenetics www.childrensonocologygroup.org 4 9/21/2016 INSS Staging High Risk Neuroblastoma Long term survival is about 34 - 40% with High Risk Group • INSS Stage 4 > 18 months of age • INSS Stage 4 with N‐MYC, regardless of age • INSS Stage 4 between 12 –18 months of age with unfavorable histology and or diploid DNA content • INSS Stage 3 with N‐MYC amplification, regardless of age • INSS Stage 3 with unfavorable histology, greater than 18 months of age • INSS Stage 2 with N‐MYC amplification, regardless of age • INSS Stage 4S with N‐MYC amplification At time of diagnosis, 78% of children and 43% of infants have www.childrensonocologygroup.org stage 3 or 4 disease www.cancer.org Treatment of High Risk Neuroblastoma Prognosis • 5 year survival for infants is 83%, children age 1 ‐ 4 • Patients receive 6 cycles of Induction chemotherapy on ANBL0532 years is 55%, and children 5 years and older is 40% ▫ Cycle 1: Cyclophosphamide/Topotecan • Two year survival in stage 3 or 4 is 10 ‐ 30% ▫ Cycle 2: Cyclophosphamide/Topotecan ▫ Cycle 3: Cisplatin/Etoposide ▫ Cycle 4: Vincristine/Doxorubicin/Cyclophosphamide ▫ Cycle 5: Cisplatin/Etoposide ‐‐‐‐ SURGERY‐‐‐‐ ▫ Cycle 6: Vincristine/Doxorubicin/Cyclophosphamide • Autologous stem cell transplant ▫ Two transplants Thiotepa and Cyclophosphamide Carboplatin, Etoposide, Melphalan www.cancer.gov • Radiation www.childrensoncologygroup.org Dinutuximab Citation Study Design and Treatment Regimen Results Conclusion Dinutuximab (Unituxan®) A.L. Yu, Design: Drug Control Inclusion of 2010 Randomized, Phase 3 Study Number Number immunotherapy to (%) (%) (n=113) (n=113) isotretinoin therapy • Anti‐GD2 monoclonal antibody Treatment: resulted in significantly 2‐Yr 66±5 46±5 Addition of ch14.18 with GM‐CSF and Event‐ superior event‐free and • COG studies ANBL0032 and ANBL0931 interleukin‐2 to isotretinoin therapy free overall survival.
Load more

Recommended publications
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Dinutuximab for the Treatment of Pediatric Patients with High-Risk Neuroblastoma
    Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma Jaume Mora To cite this article: Jaume Mora (2016): Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma, Expert Review of Clinical Pharmacology, DOI: 10.1586/17512433.2016.1160775 To link to this article: http://dx.doi.org/10.1586/17512433.2016.1160775 Accepted author version posted online: 02 Mar 2016. Published online: 21 Mar 2016. Submit your article to this journal Article views: 21 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierj20 Download by: [Hospital Sant Joan de Deu], [Jaume Mora] Date: 30 March 2016, At: 23:12 EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016 http://dx.doi.org/10.1586/17512433.2016.1160775 DRUG PROFILE Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma Jaume Mora Department of Pediatric Onco-Hematology and Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Passeig Sant Joan de Déu, Barcelona, Spain ABSTRACT ARTICLE HISTORY Neuroblastoma (NB) is the most common extra cranial solid tumor of childhood, with 60% of patients Received 14 December 2015 presenting with high risk (HR) NB by means of clinical, pathological and biological features. The 5-year Accepted 29 February 2016 survival rate for HR-NB remains below 40%, with the majority of patients suffering relapse from Published online chemorefractory tumor. Immunotherapy is the main strategy against minimal residual disease and 21 March 2016 clinical experience has mostly focused on monoclonal antibodies (MoAb) against the glycolipid dis- KEYWORDS ialoganglioside GD2.
    [Show full text]
  • Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
    Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory.
    [Show full text]
  • And Grand Overview
    Welcome and Grand Overview Rose Aurigemma, PhD Acting Associate Director, Developmental Therapeutics Program Division of Cancer Treatment & Diagnosis, NCI July 23, 2021 Thank You to the Organizing Committee Weiwei Chen, Program Director, PTGB, DTP Rachelle Salomon, Program Director, BRB, DTP Sharad Verma, Program Director, PTGB, DTP Jason Yovandich, Chief, BRB, DTP Sundar Venkatachalam, Chief, PTGB, DTP 2 Introduction to the Developmental Therapeutics Program In 1955, congress created the Cancer Chemotherapy National Service Center which evolved, both structurally and functionally, into today’s Developmental Therapeutics Program (DTP). DTP’s involvement in the discovery or development of many anticancer therapeutics on the market today demonstrates its indelible impact on efforts to improve the health and well-being of people with cancer. 3 Approved Cancer Therapies with DTP Assistance 2018 Moxetumomab pasudotox-tdfk 1983 Etoposide (NSC 141540) 2015 Dinutuximab (Unituxin, NSC 764038) 1982 Streptozotocin (NSC 85998) Ecteinascidin 743 (NSC 648766) 1979 Daunorubicin (NSC 82151) 2012 Omacetaxine (homoharringtonine, NSC 141633) 1978 Cisplatin (cis-platinum) (NSC 119875) 2010 Eribulin (NSC 707389) 1977 Carmustine (BCNU) (NSC 409962) Sipuleucel-T (NSC 720270) 1976 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosurea (CCNU) 2009 Romidepsin (NSC 630176) (NSC 9037) Pralatrexate (NSC 713204) 1975 Dacarbazine (NSC 45388) 2004 Azacitidine (NSC 102816) 1974 Doxorubicin (NSC 123127) Cetuximab (NSC 632307) Mitomycin C (NSC 26980) 2003 Bortezomib (NSC 681239) 1973
    [Show full text]
  • Qarziba, INN-Dinutuximab Beta
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Qarziba 4.5 mg/mL concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mL of concentrate contains 4.5 mg dinutuximab beta. Each vial contains 20 mg dinutuximab beta in 4.5 mL. Dinutuximab beta is a mouse-human chimeric monoclonal IgG1 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion Clear, colourless liquid. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin-2 (IL-2). 4.2 Posology and method of administration Qarziba is restricted to hospital-use only and must be administered under the supervision of a physician experienced in the use of oncological therapies.
    [Show full text]
  • High Risk Therapy Made Easy: Supporting High Risk Patients Through Complex Therapy
    8/21/2018 High Risk Therapy Made Easy: Supporting high risk patients through complex therapy Lori Ranney, MSN, APRN, CPNP, CPHON Mylynda Livingston, MSN, APRN, AC PC-PNP, CPON Teresa Herriage, DNP, APRN, CPNP, CPHON Children’s Minnesota Disclaimers and Confidentiality Protections Children’s Minnesota makes no representations or warranties about the accuracy, reliability, or completeness of the content. Content is provided “as is” and is for informational use only. It is not a substitute for professional medical advice, diagnosis, or treatment. Children’s disclaims all warranties, express or implied, statutory or otherwise, including without limitation the implied warranties of merchantability, non-infringement of third parties’ rights, and fitness for a particular purpose. This content was developed for use in Children’s patient care environment and may not be suitable for use in other patient care environments. Children’s does not endorse, certify, or assess third parties’ competency. You hold all responsibility for your use or nonuse of the content. Children’s shall not be liable for claims, losses, or damages arising from or related to any use or misuse of the content. This content and its related discussions are privileged and confidential under Minnesota’s peer review statute (Minn. Stat. § 145.61 et. seq.). Do not disclose unless appropriately authorized. Notwithstanding the foregoing, content may be subject to copyright or trademark law; use of such information requires Children’s permission. This content may include patient protected health information. You agree to comply with all applicable state and federal laws protecting patient privacy and security including the Minnesota Health Records Act and the Health Insurance Portability and Accountability Act and its implementing regulations as amended from time to time.
    [Show full text]
  • Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
    pharmaceutics Review Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Marco Cavaco, Diana Gaspar, Miguel ARB Castanho * and Vera Neves * Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (M.A.R.B.C.); [email protected] (V.N.) Received: 19 November 2019; Accepted: 28 December 2019; Published: 13 January 2020 Abstract: The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood–brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.
    [Show full text]
  • WO 2017/055313 Al 6 April 2017 (06.04.2017) W P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/055313 Al 6 April 2017 (06.04.2017) W P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 233/54 (2006.01) A61K 31/4178 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4164 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 16/073040 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 28 September 2016 (28.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 15 188027.5 1 October 201 5 (01. 10.2015) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: BAYER PHARMA AKTIENGESELL- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, SCHAFT [DE/DE]; Mullerstr.
    [Show full text]
  • Dinutuximab Combination Therapy Becomes Frst Approval for High-Risk Neuroblastoma
    Community Translations Dinutuximab combination therapy becomes frst approval for high-risk neuroblastoma he approval of dinutuximab by the US Food and Drug Administration marks the third approval for What's new, what's important a pediatric cancer and the frst for patients with The US Food and Drug Administration (FDA) approved dinutux- T 1 high-risk neuroblastoma. Dinutuximab is an immuno- imab as part of frst-line therapy for pediatric patients with high- therapeutic agent; a monoclonal antibody (mAb) targeting risk neuroblastoma. a glycolipid that is highly expressed on the surface of neu- Dinutuximab is a GD2-binding monoclonal antibody indi- roblastoma cells. cated, in combination with granulocyte-macrophage colony- Te mAb was approved in combination with the cyto- stimulating factor, interleukin-2, and 13-cis-retinoic acid for the kines granulocyte macrophage colony-stimulating factor treatment of pediatric patients with high-risk neuroblastoma (GM-CSF) and interleukin-2 (IL-2), and the oral reti- who achieve at least a partial response to prior frst-line multia- noid isotretinoin (RA). Te approval was based on a piv- gent, multimodality therapy. otal, phase 3, multicenter, open-label, randomized trial The pivotal study showed that after 3 years of follow-up, conducted by the Children’s Oncology Group between 63% of patients who received the dinutuximab combination October 2001 and January 2009 that was stopped early were alive and free of cancer growth or recurrence, compared after the combination demonstrated superiority over stan- with 46% of patients in the control arm. In an updated analy- dard therapy with respect to event-free survival (EFS).2 sis of survival, 73% of patients who received the dinutuximab Two hundred and twenty-six patients (mostly pediatric combination were alive, compared with 58% of those in the patients, though age up to 31 years at diagnosis was allowed) control arm.
    [Show full text]
  • CDER List of Licensed Biological Products With
    Center for Drug Evaluation and Research List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date DATE OF FIRST REFERENCE PRODUCT DATE OF LICENSURE LICENSURE EXCLUSIVITY EXPIRY DATE INTERCHANGEABLE (I)/ BLA STN PRODUCT (PROPER) NAME PROPRIETARY NAME (mo/day/yr) (mo/day/yr) (mo/day/yr) BIOSIMILAR (B) WITHDRAWN 125118 abatacept Orencia 12/23/05 NA NA 103575 abciximab ReoPro 12/22/94 NA NA Yes 125274 abobotulinumtoxinA Dysport 04/29/09 125057 adalimumab Humira 12/31/02 NA NA 761071 adalimumab-adaz Hyrimoz 10/30/18 B 761058 adalimumab-adbm Cyltezo 08/25/17 B 761118 adalimumab-afzb Abrilada 11/15/19 B 761024 adalimumab-atto Amjevita 09/23/16 B 761059 adalimumab-bwwd Hadlima 07/23/19 B 125427 ado-trastuzumab emtansine Kadcyla 02/22/13 125387 aflibercept Eylea 11/18/11 103979 agalsidase beta Fabrazyme 04/24/03 NA NA 125431 albiglutide Tanzeum 04/15/14 017835 albumin chromated CR-51 serum Chromalbin 02/23/76 103293 aldesleukin Proleukin 05/05/92 NA NA 103948 alemtuzumab Campath, Lemtrada 05/07/01 NA NA 125141 alglucosidase alfa Myozyme 04/28/06 NA NA 125291 alglucosidase alfa Lumizyme 05/24/10 125559 alirocumab Praluent 07/24/15 103172 alteplase, cathflo activase Activase 11/13/87 NA NA 103950 anakinra Kineret 11/14/01 NA NA 020304 aprotinin Trasylol 12/29/93 125513 asfotase alfa Strensiq 10/23/15 101063 asparaginase Elspar 01/10/78 NA NA 125359 asparaginase erwinia chrysanthemi Erwinaze 11/18/11 761034 atezolizumab Tecentriq 05/18/16 761049 avelumab Bavencio 03/23/17
    [Show full text]
  • Early Phase Clinical Studies Update
    Early Phase and/or Targeted Therapy Studies in Pediatric Oncology in Switzerland Study Agent(s) Phase Indication Age Open Sites Contact / PI BEACON ± Dinutuximab beta (rando 2b Neuroblastoma (relapsed or refractory) 1-21y Zürich, Nicolas Gerber 2:+ with possibility of cross- Lausanne Maja Beck-Popovic over) + backbone with TMZ, or TMZ+topotecan (rando) T-VEC Talimogene laherparepvec 1 Relapsed or refractory solid (non-CNS 0-21y Zürich, Felix Niggli (oncolytic virus) tumors) with at least 1 injectable (non- Basel Thomas Kühne visceral) lesion Venetoclax Venetoclax 1 Relapsed or refractory tumors: solid tumors 0-25y Zürich Nicolas Gerber with BCL-2 expression and AML/ALL/lymphoma Dabrafenib/ Dabrafenib and Trametinib 2 High-grade glioma (BRAF V600 mutation 6-18y Zürich Nicolas Gerber Trametinib positive, relapsed or refractory), Low Grade Glioma (BRAF V600 mutation positive, unresectable tumor requiring treatment: for LGG only as first non-surgical treatment) Larotrectinib Larotrectinib 1/2 Advanced solid tumors (CNS and Non-CNS) 0-21y (incl. of Zürich Nicolas Gerber (Phase 1 expansion cohort and Phase 2: older pat. with NTRK gene fusion required [or for infantile ped. tumor fibrosarcoma, congenital mesoblastic types to be Solid Tumors Solid nephroma, or secretory breast cancer: discussed with ETV6 rearrangement]. Phase II: also benign sponsor) tumors with NTRK fusion eligible) Claudia Althaus, Clinical Trials Manager ([email protected]) University Children's Hospital, Zürich Nicolas Gerber, Ped. Oncologist ([email protected]) 19 Dec 2019 Page 1 / 2 Solid Tumors Solid Fimepinostat Fimepinostat (start 2 days 1 Newly Diagnosed Diffuse Intrinsic Pontine 3-39y Zürich Nicolas Gerber before biopsy/surgery!) Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG).
    [Show full text]
  • (2006.01) A61k 31/517 (2006.01) Tr, Tt, Tz, Ua, Ug, Us, Uz, Vc, Vn, Za, Zm, Zw
    ( 1 (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C07D 403/04 (2006.01) A61K 31/517 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. C07D 403/14 (2006.01) A61K 31/519 (2006.01) (84) Designated States (unless otherwise indicated, for every C07D 407/14 (2006.01) A61P 35/00 (2006.01) kind of regional protection available) . ARIPO (BW, GH, C07D 487/04 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (21) International Application Number: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, PCT/EP20 19/055 160 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (22) International Filing Date: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 0 1 March 2019 (01.03.2019) TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, (25) Filing Language: English KM, ML, MR, NE, SN, TD, TG). (26) Publication Language: English Declarations under Rule 4.17: (30) Priority Data: — as to applicant's entitlement to apply for and be granted a 18160540.3 07 March 2018 (07.03.2018) EP patent (Rule 4.17(H)) (71) Applicants: BAYER AKTIENGESELLSCHAFT Published: [DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen — with international search report (Art. 21(3)) (DE). BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE] ; Mtillerstr. 178, 13353 Berlin (DE). (72) Inventors: NGUYEN, Duy; Heinrich-Heine-Stralk 27, 10179 Berlin (DE).
    [Show full text]